Viable cell growth inhibition of compounds BMX-IN-1, JS10, JS11 and JS24 in a panel of prostate, brain, blood, breast, ovary, lung and lymphoid cancer cellsa.
| Tissue | Cell line | BMX-IN-1 | JS24 | JS10 | JS11 |
|---|---|---|---|---|---|
| Prostate | LNCaP | 1.81 ± 0.05 | 4.4 ± NC | 9.7 ± NC | 10.41 ± NC |
| 22 RV1 | 2.07 ± 0.06 | 6.66 ± 0.09 | 4.86 ± 0.11 | 7.3 ± NC | |
| PC3 | 10.98 ± 1.13 | 4.8 ± NC | ND | 20.12 ± NC | |
| DU145 | 17.7 ± NC | ND | ND | ND | |
| Brain | U-87MG | 5.33 ± 0.19 | 5.04 ± 0.01 | ND | ND |
| SK-N-MC | 2.36 ± NC | 8.53 ± 0.44 | 11.19 ± NC | 8.24 ± NC | |
| Blood | Jurkat | 5.99 ± NC | 5.48 ± ND | 9.71 ± 1.48 | 6.36 ± 0.17 |
| Kasumi | 3.13 ± 0.06 | 5.12 ± 0.12 | 4.37 ± 0.04 | 10.14 ± 0.07 | |
| Breast | MDA-MB-231 | 23.61 ± 0.48 | ND | ND | ND |
| Ovary | CAOV3 | 7.68 ± 0.13 | 8.56 ± NC | 17.30 ± NC | 19.31 ± NC |
| OVCAR3 | ND | ND | ND | ND | |
| Bone marrow | H1299 | ND | 7.28 ± 0.37 | 19.42 ± NC | ND |
| Lung | RS4(11) | 1.176 ± 0.06 | 2.09 ± NC | 5.06 ± NC | 6.66 ± NC |
| Lymphoid | DAUDI | 1.68 ± 0.07 | 1.27 ± 0.05 | 2.57 ± 0.09 | 4.57 ± 0.12 |
a
Viable cell growth was measured after 72 h incubation in 386 well-plate format. GI50 values were tested in triplicate and are reported as the mean ± SD in μM. ND, non-determined, no growth inhibition observed within the concentrations tested. NC, non-calculated. When ambiguous fit was observed curves were top (100%) and bottom (0%) constrained and GI50 was determined with 4-P least squares fit. In these cases, SD is not calculated by GraphPad Prism 8.